Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

20.52 -2.98 (-12.68%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	7,194,548
Open	21.54
Bid (Size)	20.40 (1,000)
Ask (Size)	20.45 (200)
Prev. Close	23.50
Today's Range	19.61 - 23.17
52wk Range	18.41 - 46.27
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 15:00 EST

From Schall Law

Via GlobeNewswire

RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty ↗

Today 12:25 EST

Ultragenyx said on Thursday that the FDA has again refused approval for UX111 in the treatment of Sanfilippo syndrome type A.

Via Stocktwits

Performance

YTD	-13.1%	-13.1%
1 Month	-14.9%	-14.9%
3 Month	-37.6%	-37.6%
6 Month	-29.3%	-29.3%
1 Year	-52.8%	-52.8%

More News

Class Action Announcement RARE: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc. (RARE)

Today 10:45 EST

Via NewMediaWire

Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Q4 Revenue Beat, Wider Loss, and Announces Restructuring ↗

February 12, 2026

Via Chartmill

RARE Stock Slips 3% Today — What’s Up With Ultragenyx’s Gene Therapy For Sanfilippo Syndrome? ↗

January 30, 2026

Via Stocktwits

Class Action Announcement RARE: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc. (RARE)

Today 10:45 EST

Via TheNewswire.com

Ultragenyx (RARE) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Via The Motley Fool

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

February 12, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

February 12, 2026

From SkyMedia, LLC

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

February 10, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.

February 10, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 10, 2026

From Schall Law

Via GlobeNewswire

RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ultragenyx Pharmaceutical Inc. Class Action

February 09, 2026

From Robbins LLP

Via GlobeNewswire

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

February 06, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE

February 06, 2026

From DJS Law Group

Via Business Wire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

February 05, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 05, 2026

From The Schall Law Firm

Via Business Wire

ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. and Encourages Investors to Contact the Firm

February 05, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

February 05, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights

February 05, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit

February 04, 2026

From Robbins LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in

February 03, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

January 30, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 20.52

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 02/13/26 04:00 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.45B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.